T2 Biosystems Inc (OQ:TTOO)

Business Focus: Advanced Medical Equipment & Technology

Apr 24, 2024 09:00 am ET
T2 Biosystems to Report First Quarter 2024 Financial Results and Business Updates on May 6, 2024
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2024 and business updates after market close...
Apr 11, 2024 04:05 pm ET
T2 Biosystems Shareholders Vote for CRG Debt Conversion into Equity
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced results from the special meeting of stockholders on April 11, 2024. T2 Biosystems Stockholders voted for...
Mar 28, 2024 09:00 am ET
T2 Biosystems Announces Extension of Multi-Year Capital Equipment Supplier Agreement with Vizient, Inc.
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its multi-year capital equipment supplier agreement with Vizient, Inc., the largest member-driven...
Mar 20, 2024 07:30 am ET
T2 Biosystems Unveils T2Lyme Launch Plans and Provides Additional Business Updates
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans for the T2Lyme Panel commercial launch and provided recent business updates....
Mar 19, 2024 09:00 am ET
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch...
Mar 18, 2024 09:00 am ET
T2 Biosystems Announces New Publication Highlighting the Clinical Benefits and Performance of the T2Resistance Panel
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the publication of a new study highlighting the clinical benefits and performance of...
Mar 12, 2024 09:00 am ET
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirement
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Nasdaq Hearings Panel has granted the Company's request for continued listing on the Nasdaq...
Feb 15, 2024 04:06 pm ET
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2023 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full...
Feb 15, 2024 04:04 pm ET
T2 Biosystems Announces Agreement with CRG for the Conversion of $15 Million of CRG Term Loan into Equity
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the entrance into a definitive agreement to convert $15 million of its term loan with entities...
Feb 15, 2024 04:02 pm ET
T2 Biosystems Announces Commercial Expansion Through Distributors in Europe and Asia
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of territory exclusive distribution agreements for new geographies in the Netherlands,...
Feb 12, 2024 09:00 am ET
T2 Biosystems Receives FDA 510(k) Clearance for the Expanded T2Bacteria Panel
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the expanded...
Feb 07, 2024 04:05 pm ET
T2 Biosystems to Report Fourth Quarter and Full Year 2023 Financial Results and Business Updates on February 15, 2024
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2023 and business updates...
Feb 07, 2024 09:00 am ET
U.S. Department of Health and Human Services and Steven and Alexandra Cohen Foundation Name T2 Biosystems a Phase 2 Winner in the LymeX Diagnostics Prize
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation...
Jan 18, 2024 09:00 am ET
T2 Biosystems Announces Participation in NIH-funded Antibacterial Resistance Leadership Group (ARLG) Pilot Study for Pneumonia Patients
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced participation in the NIH-funded Antibacterial Resistance Leadership Group (ARLG) pilot study for...
Jan 03, 2024 09:00 am ET
T2 Biosystems Announces FDA 510(k) Submission to Expand Use of the FDA-Cleared T2Candida Panel to Include Pediatric Testing
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to...
Nov 03, 2023 09:00 am ET
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital...
Nov 01, 2023 09:00 am ET
T2 Biosystems Regains Compliance with Nasdaq Listing Requirements
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on October 31, 2023 it received written notice from the Nasdaq Listing...
Oct 31, 2023 09:31 am ET
Thinking about buying stock in T2 Biosystems, Cybin, Alphabet Inc, Archer Aviation, or MeiraGTx Holdings?
NEW YORK, Oct. 31, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, CYBN, GOOGL, ACHR, and MGTX.
Oct 24, 2023 04:05 pm ET
T2 Biosystems Highlights New Clinical Data Presented at IDWeek 2023 Conference
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted four new studies supporting the T2Bacteria® Panel, the T2Candida® Panel and the T2Resistance® Panel...
Oct 23, 2023 09:00 am ET
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”). The...
Oct 13, 2023 09:31 am ET
Thinking about buying stock in T2 Biosystems, Lucid Group, Femasys, Groupon Inc, or Phio Pharmaceuticals?
NEW YORK, Oct. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, LCID, FEMY, GRPN, and PHIO.
Oct 12, 2023 04:05 pm ET
T2 Biosystems Announces Preliminary Third Quarter 2023 Financial Results and Business Updates
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quarter ended September 30, 2023...
Oct 12, 2023 04:02 pm ET
T2 Biosystems Announces FDA 510(k) Submission to Expand the Pathogen Detection on its FDA-Cleared T2Bacteria Panel to Include Detection of Acinetobacter baumannii
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) to...
Oct 12, 2023 09:00 am ET
T2 Biosystems Announces Reverse Stock Split Effective Today
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Company’s board of directors (the “Board”) has approved a reverse stock split...
Oct 06, 2023 04:07 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to nine new employees. The awards were made on October 2, 2023, under the T2 Biosystems’ Inducement...
Oct 05, 2023 04:05 pm ET
T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report preliminary financial results for the third quarter 2023 and business updates after...
Oct 02, 2023 12:30 pm ET
SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of T2 Biosystems, Inc. (NASDAQ: TTOO) and Encourages Investors to Contact the Firm
Kaskela Law LLC announces that it is investigating T2 Biosystems, Inc. (NASDAQ: TTOO) (“T2”) on behalf of the company’s investors. Since October 2022, shares of T2’s common stock have declined in value from a trading price of over $5.00 per share...
Sep 21, 2023 09:31 am ET
Thinking about buying stock in Murphy Canyon Acquisition Corp, Alliance Entertainment Holding, Fitell Corp, T2 Biosystems, or Aurora Cannabis?
NEW YORK, Sept. 21, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MURF, AENT, FTEL, TTOO, and ACB.
Sep 19, 2023 09:00 am ET
T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the...
Sep 18, 2023 09:31 am ET
Thinking about buying stock in Canopy Growth, Lithium Americas, T2 Biosystems, Taysha Gene Therapies, or Archer Aviation?
NEW YORK, Sept. 18, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CGC, LAC, TTOO, TSHA, and ACHR.
Sep 15, 2023 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees. The awards were made on September 7, 2023, under the T2 Biosystems’...
Sep 13, 2023 09:31 am ET
Thinking about buying stock in Nature Wood Group, Sigma Lithium, Fusion Pharmaceuticals, T2 Biosystems, or Tilray Brands?
NEW YORK, Sept. 13, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NWGL, SGML, FUSN, TTOO, and TLRY.
Sep 07, 2023 04:05 pm ET
T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place...
Aug 28, 2023 08:30 am ET
T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today praised actions taken by the U.S. Centers for Disease Control and Prevention (CDC) aimed at optimizing hospital...
Aug 15, 2023 10:20 am ET
Sidoti Events, LLC’s Virtual August Micro-Cap Conference
NEW YORK, NY / ACCESSWIRE / August 15, 2023 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 16-17, 2023. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
Aug 09, 2023 08:30 am ET
T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8,...
Aug 07, 2023 04:05 pm ET
T2 Biosystems Announces Second Quarter 2023 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the second quarter ended June 30, 2023. Recent Financial and...
Jul 31, 2023 08:30 am ET
T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through...
Jul 28, 2023 08:30 am ET
T2 Biosystems to Attend Upcoming Investor Conferences
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2023: Canaccord Genuity...
Jul 24, 2023 04:05 pm ET
T2 Biosystems to Report Second Quarter 2023 Financial Results on August 7, 2023
T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2023 after market close Monday, August 7,...
Jul 21, 2023 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to fourteen new employees. The awards were made on June 26, 2023, under the T2 Biosystems’ Inducement...
Jul 20, 2023 08:30 am ET
T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the...
Jul 12, 2023 08:30 am ET
T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the second quarter 2023. Recent Financial...
Jul 06, 2023 08:00 am ET
T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC...
Jun 09, 2023 09:15 am ET
T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced a collaborative relationship with Vanderbilt University Medical Center’s (VUMC) Learning Healthcare...
Jun 05, 2023 09:00 am ET
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough...
May 30, 2023 09:00 am ET
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-driven T2Dx® Instruments in Company history. T2 Biosystems’...
May 23, 2023 08:05 am ET
T2 Biosystems Announces First Quarter 2023 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the first quarter ended March 31, 2023. Recent Financial and...
May 23, 2023 08:01 am ET
T2 Biosystems Announces Exploration of Strategic Alternatives and the Implementation of a Restructuring Program
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced it has initiated a process to explore a range of strategic alternatives focused on maximizing value. To...
May 23, 2023 08:00 am ET
T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for...
May 22, 2023 08:15 am ET
T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023
T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today it has rescheduled its first quarter 2023 financial results reporting to before market open on Tuesday,...
May 19, 2023 09:22 am ET
WBB Research Institute Webcast Highlighted the Need For a Global Response to Candida auris and Other Deadly Antimicrobial Resistant Pathogens
Cranford, New Jersey--(Newsfile Corp. - May 19, 2023) - WBB Research Institute (WBBRI) hosted a Demi-Colton Virtual Salon on the need for a global response to Candida auris and other deadly pathogens. Antimicrobial resistant C. auris is becoming a major public health threat and is found in over 30 countries causing outbreaks in hospitals, nursing homes, and other healthcare settings. It or another emerging antimicrobial resistant pathogen will likely be the cause of the next global pandemic. Scynexis (NASDAQ: SCYX) and T2 Biosystems (NASDAQ: TTOO) were two of the public companies that participated in the webinar, which highlighted the need for increased collaboration between academia, government agencies and the private sector to accelerate the development and use of rapid blood diagnostics and novel therapeutics.
May 17, 2023 04:05 pm ET
T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023
T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has rescheduled its first quarter 2023 financial results reporting to before market open on...
May 15, 2023 04:05 pm ET
T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today it has postponed its first quarter 2023 earnings release and conference call. The delay is a result of...
May 01, 2023 04:05 pm ET
T2 Biosystems to Report First Quarter 2023 Financial Results on May 15, 2023
T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2023 after market close on Monday, May 15,...
Apr 26, 2023 08:30 am ET
T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today highlighted new clinical data supporting the T2Bacteria® Panel and the T2Candida® Panel, that was recently...
Apr 19, 2023 09:46 am ET
Thinking about buying stock in AMC Entertainment, Exxon Mobil, Walmart, T2 Biosystems, or JPMorgan?
NEW YORK, April 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AMC, XOM, WMT, TTOO, and JPM.
Apr 05, 2023 08:00 am ET
T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the availability of a new webinar and white paper highlighting the T2Candida® Panel clinical data and...
Mar 23, 2023 09:00 am ET
T2 Biosystems Affirms Plans to Add Candida Auris Detection to the FDA-Cleared T2Candida Panel
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today affirmed plans to add detection of the fungal pathogen Candida auris to the Company’s FDA-cleared and CE marked...
Mar 13, 2023 04:05 pm ET
T2 Biosystems Announces Fourth Quarter and Full Year 2022 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the fourth quarter and full year ended December 31, 2022....
Mar 03, 2023 08:00 am ET
T2 Biosystems to Report Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the fourth quarter and full year 2022 after market close on...
Feb 15, 2023 07:30 am ET
T2 Biosystems Announces Pricing of $12 Million Public Offering
T2 Biosystems, Inc. (NASDAQ: TTOO) today announced the pricing of its previously announced underwritten public offering of 11,111,111 shares of common stock (or common stock equivalents) and warrants to purchase up to 22,222,222 shares of common...
Feb 13, 2023 04:19 pm ET
T2 Biosystems Announces Proposed Public Offering
T2 Biosystems, Inc. (NASDAQ: TTOO) today announced that it is commencing an underwritten public offering of shares of its common stock (or common stock equivalents) and warrants to purchase shares of its common stock. All of the securities are...
Feb 13, 2023 04:01 pm ET
T2 Biosystems Announces Positive Results upon Completion of U.S. Clinical Evaluation for the T2Biothreat Panel
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced positive results upon completion of the U.S. clinical evaluation for the T2Biothreat™ Panel. "We...
Feb 06, 2023 04:05 pm ET
T2 Biosystems Advances to the Phase 2 in HHS and the Steven and Alexandra Cohen Foundation’s LymeX Diagnostics Prize
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has advanced to the Phase 2 accelerator in the U.S. Department of Health and Human Services...
Feb 03, 2023 04:30 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, and antibiotic resistance genes, announced today that it issued inducement awards to fourteen new employees. The awards were made on January 30, 2023,...
Jan 23, 2023 04:30 pm ET
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2022. Full...
Dec 28, 2022 09:00 am ET
T2 Biosystems Announces Extension of Multiyear Innovative Technology Contract with Vizient, Inc.
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that its Innovative Technology contract with Vizient, Inc., the largest member-driven health care...
Dec 08, 2022 08:28 am ET
T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Ther
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the publication of a peer-reviewed article published by Oxford University Press on behalf of the...
Nov 10, 2022 04:05 pm ET
T2 Biosystems Announces Third Quarter 2022 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the third quarter ended September 30, 2022. Recent Commercial and...
Nov 10, 2022 04:04 pm ET
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”). The...
Nov 09, 2022 04:05 pm ET
T2 Biosystems to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity MedTech, Diagnostics and Digital Health &...
Nov 07, 2022 08:30 am ET
HHS and the Cohen Foundation Name T2 Biosystems a Phase 1 Winner in LymeX Diagnostics Prize
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the U.S. Department of Health and Human Services (“HHS”) and the Steven & Alexandra Cohen Foundation...
Nov 01, 2022 08:30 am ET
T2 Biosystems Regains Compliance with Nasdaq’s Minimum Bid Price Rule
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (NASDAQ) on October 31,...
Oct 31, 2022 05:56 pm ET
T2 Biosystems to Report Third Quarter 2022 Financial Results on November 10, 2022
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2022 after market close on...
Oct 20, 2022 09:05 am ET
T2 Biosystems Initiates Studies to Add Acinetobacter Baumannii to the FDA-Cleared T2Bacteria Panel
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has initiated studies to expand the number of pathogens detected on the FDA-cleared T2Bacteria®...
Oct 14, 2022 08:30 am ET
T2 Biosystems Highlights Multiple New Studies Demonstrating Improved Rapid Detection Across Several Patient Populations
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the publication of three new, peer-reviewed studies that demonstrate the clinical value of the use of...
Oct 13, 2022 09:00 am ET
T2 Biosystems Announces Plan to Commercialize a Diagnostic Test for Early Lyme Disease
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to complete development of, and commercialize, a diagnostic test for the detection of early Lyme...
Oct 13, 2022 08:33 am ET
Thinking about buying stock in T2 Biosystems, WISeKey, Immunic, Meta Materials, or Applied DNA Sciences?
NEW YORK, Oct. 13, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, WKEY, IMUX, MMAT, and APDN.
Oct 12, 2022 08:35 am ET
T2 Biosystems Announces Preliminary Third Quarter 2022 Financial Results and Updates 2022 Financial Outlook
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the third quarter ended September 30, 2022....
Oct 12, 2022 08:30 am ET
T2 Biosystems Announces Reverse Stock Split Effective Today
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that the Company’s board of directors (the “Board”) has approved a reverse stock split...
Sep 29, 2022 08:30 am ET
T2 Biosystems Announces BARDA Exercise of Contract Option 3 Valued at $3.7 Million
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the...
Sep 23, 2022 10:50 am ET
Thinking about buying stock in Avenue Therapeutics, Color Star Technology, T2 Biosystems, NanoVibronix, or Energy Transfer?
NEW YORK, Sept. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ATXI, CSCW, TTOO, NAOV, and ET.
Sep 22, 2022 04:05 pm ET
T2 Biosystems Announces Commercial Expansion Through Distributor in Baltic Region
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the execution of a territory exclusive distribution agreement in the Baltic Region, including Lithuania,...
Sep 08, 2022 04:05 pm ET
T2 Biosystems to Participate in the H.C. Wainwright Global Investment Conference
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming H.C. Wainwright Global Investment Conference in New York, New York....
Aug 18, 2022 04:05 pm ET
T2 Biosystems to Present at the Inaugural Gilmartin Group Emerging Growth Company Showcase
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to present at the upcoming Inaugural Gilmartin Group Emerging Growth Company Showcase, taking...
Aug 17, 2022 12:37 pm ET
Thinking about buying stock in Endo International, T2 Biosystems, SoFi Technologies, Nu Holdings, or Bloom Energy?
NEW YORK, Aug. 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ENDP, TTOO, SOFI, NU, and BE.
Aug 16, 2022 10:30 am ET
Thinking about buying stock in T2 Biosystems, My Size, Helbiz, Bath & Body Works, or IONQ?
NEW YORK, Aug. 16, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, MYSZ, HLBZ, BBWI, and IONQ.
Aug 15, 2022 04:05 pm ET
T2 Biosystems Announces Second Quarter 2022 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the second quarter ended June 30, 2022. Recent Highlights...
Aug 15, 2022 10:55 am ET
Thinking about buying stock in T2 Biosystems, Mullen Automotive, Plug Power, Tilray, or Li Auto?
NEW YORK, Aug. 15, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, MULN, PLUG, TLRY, and LI.
Aug 12, 2022 11:36 am ET
Thinking about buying stock in T2 Biosystems, Twin Vee Powercats, Rivian Automotive, DraftKings, or Pacific Biosciences of California?
NEW YORK, Aug. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, VEEE, RIVN, DKNG, and PACB.
Aug 11, 2022 11:25 am ET
Thinking about buying stock in T2 Biosystems, AcelRx Pharmaceuticals, Ginkgo Bioworks, BioNano Genomics, or AMC Entertainment?
NEW YORK, Aug. 11, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, ACRX, DNA, BNGO, and AMC.
Aug 10, 2022 10:40 am ET
Thinking about buying stock in Euro Tech, T2 Biosystems, Bed Bath & Beyond, SoFi Technologies, or Redbox?
NEW YORK, Aug. 10, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CLWT, TTOO, BBBY, SOFI, and RDBX.
Aug 09, 2022 10:59 am ET
Thinking about buying stock in T2 Biosystems, Palantir Technologies, Tuesday Morning, Shell, or Ironsource?
NEW YORK, Aug. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, PLTR, TUEM, SHEL, and IS.
Aug 09, 2022 08:30 am ET
T2 Biosystems to Explore Potential to Develop Rapid Molecular Diagnostic Test for Monkeypox Virus
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today plans to explore the potential to develop a rapid molecular diagnostic test for detection of the...
Aug 05, 2022 10:55 am ET
Thinking about buying stock in Marker Therapeutics, Helius Medical Technologies, T2 Biosystems, Missfresh, or LYFT?
NEW YORK, Aug. 5, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MRKR, HSDT, TTOO, MF, and LYFT.
Jul 29, 2022 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Awards
T2 Biosystems, Inc. (NASDAQ: TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to twelve new employees. The awards were made on July 25, 2022, under the T2 Biosystems’ Inducement...
Jul 28, 2022 04:32 pm ET
T2 Biosystems to Report Second Quarter 2022 Financial Results on August 15, 2022
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2022 after market close on Monday, August...
Jul 27, 2022 04:05 pm ET
T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Canaccord Genuity Annual Growth Conference in Boston,...
Jul 11, 2022 08:00 am ET
T2 Biosystems Receives FDA Breakthrough Device Designation for the T2Lyme Panel
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Company’s...
Jul 06, 2022 08:30 am ET
T2 Biosystems Announces Preliminary Second Quarter 2022 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial results for the quarter ended June 30, 2022. Recent Highlights...
Jun 15, 2022 04:05 pm ET
T2 Biosystems to Appear on the Benzinga All Access Show on June 17, 2022
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to appear on the Benzinga All Access show on Friday, June 17, 2022. Management is scheduled to be...
Jun 10, 2022 09:00 am ET
T2 Biosystems Receives Nasdaq Extension to Comply with Bid Price Rule; Company to Transfer to Nasdaq Capital Market
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension until...
May 20, 2022 09:17 am ET
T2 Biosystems Announces Issuance of U.S. Patent for Direct Detection of Lyme Disease
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Patent and Trademark Office has issued patent number 11,326,213 (the ‘213 Patent), “NMR Methods...
May 05, 2022 04:05 pm ET
T2 Biosystems Announces First Quarter 2022 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the first quarter ended March 31, 2022. Recent Highlights...
May 05, 2022 04:02 pm ET
T2 Biosystems Announces Receipt of Nasdaq Delisting Notice
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that on May 5, 2022 it received a letter from The Nasdaq Stock Market informing the Company that its...
Apr 28, 2022 08:30 am ET
T2 Biosystems Announces Formation and Members of Scientific Advisory Board
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the formation of its Scientific Advisory Board (SAB), comprising leading clinicians and researchers in...
Apr 27, 2022 08:30 am ET
T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for T2Biothreat Panel
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it has submitted an application with the U.S. Food and Drug Administration (FDA) for Breakthrough...
Apr 21, 2022 04:05 pm ET
T2 Biosystems to Report First Quarter 2022 Financial Results on May 5, 2022
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the first quarter 2022 after market close on Thursday, May 5,...
Apr 14, 2022 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to twenty-eight new employees. The awards were made on April 1, 2022, under the T2 Biosystems’...
Mar 31, 2022 04:57 pm ET
T2 Biosystems Announces BARDA Exercise of Contract Option 2B Valued at $4.4 Million
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the...
Mar 29, 2022 08:00 am ET
T2 Biosystems to Host Analyst and Investor Day on April 12, 2022
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it will host an Analyst and Investor Day on Tuesday, April 12, 2022, at 12:00pm ET. During the...
Feb 17, 2022 04:05 pm ET
T2 Biosystems Announces Fourth Quarter & Full Year 2021 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial results for the fourth quarter and full year ended December 31, 2021. Full Year 2021 and...
Feb 16, 2022 09:00 am ET
T2 Biosystems Announces Commercial Expansion Through Distributors in Norway, Finland and Türkiye
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Norway, Finland, and Türkiye. Under the terms of the agreements, T2...
Feb 15, 2022 09:27 am ET
T2 Biosystems Announces Amendment and Extension of CRG Term Loan Agreement
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the successful amendment and extension to its Term Loan Agreement with CRG Servicing LLC (“CRG”). The amendment extends both the...
Feb 08, 2022 04:05 pm ET
T2 Biosystems to Report Fourth Quarter and Full Year 2021 Financial Results on February 17, 2022
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2021 after market close on Thursday, February 17, 2022....
Feb 04, 2022 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to eighteen new employees. The awards were made on January 26, 2022, under the T2 Biosystems’...
Feb 03, 2022 08:00 am ET
T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Subvariants
T2 Biosystems, Inc. (NASDAQ:TTOO),  a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. According to the Centers for Disease Control...
Jan 11, 2022 09:05 am ET
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2021 Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2021. Recent Highlights (unaudited)...
Jan 11, 2022 09:03 am ET
T2 Biosystems Announces the Initiation of the T2Biothreat® Panel Clinical Trial
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initation of a U.S. clinical trial evaluating the performance of its T2Biothreat® Panel designed to support a submission to the U.S....
Jan 11, 2022 09:00 am ET
T2 Biosystems Announces the Initiation of the T2Resistance® Panel Clinical Trial
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the initiation of a U.S. multi-site clinical trial evaluating the performance of its T2Resistance® Panel designed to support a...
Dec 01, 2021 09:45 am ET
Thinking about buying stock in Arbutus Biopharma, Beyondspring, Cumberland Pharmaceuticals, Delta Air Lines, or T2 Biosystems?
NEW YORK, Dec. 1, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ABUS, BYSI, CPIX, DAL, and TTOO.
Dec 01, 2021 09:00 am ET
T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Variant
T2 Biosystems, Inc. (NASDAQ:TTOO),  a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects the Omicron COVID-19 variant (B.1.1.529). The World Health Organization has designated the...
Nov 19, 2021 09:00 am ET
T2 Biosystems Announces Continued International Expansion into Taiwan with Exclusive Distribution Agreement
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of a territory exclusive distribution agreement in Taiwan.   Under the terms of the agreement, T2 Biosystems will sell...
Nov 15, 2021 08:00 am ET
T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum. Management is...
Nov 08, 2021 08:00 am ET
T2 Biosystems Participates in the World Anti-Microbial Resistance Congress
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced it will participate in the 7th annual World Anti-Microbial Resistance Congress (WAMR) taking place on November 8 and 9 in Washington, DC. The...
Nov 04, 2021 04:05 pm ET
T2 Biosystems Announces Third Quarter 2021 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three months ended September 30, 2021. Recent Highlights Achieved third quarter revenue of $7.4 million,...
Nov 04, 2021 04:04 pm ET
T2 Biosystems Hires Industry Veteran Brett Giffin as Chief Commercial Officer
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Brett Giffin as its Chief Commercial Officer, effective November 8, 2021. As Chief Commercial Officer, Mr. Giffin...
Oct 22, 2021 11:25 am ET
Thinking about buying stock in Powerbridge Technologies, Naked Brand, FuelCell Energy, Ocugen, or T2 Biosystems?
NEW YORK, Oct. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PBTS, NAKD, FCEL, OCGN, and TTOO.
Oct 22, 2021 08:00 am ET
T2 Biosystems to Report Third Quarter 2021 Financial Results on November 4, 2021
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the third quarter of 2021 after market close on Thursday, November 4, 2021. Company management...
Oct 21, 2021 04:05 pm ET
T2 Biosystems Announces Distribution Agreements in Key Asia-Pacific Markets
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Singapore and South Korea. Under the terms of the agreements, T2...
Oct 19, 2021 04:05 pm ET
T2 Biosystems Appoints Laura Adams to Its Board of Directors
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the appointment of Laura Adams to its Board of Directors, effective immediately. “We are excited to have Laura join the T2 Biosystems...
Oct 15, 2021 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to twenty new employees. The awards were made on October 1, 2021 under T2 Biosystems’ Inducement Award...
Oct 14, 2021 08:55 am ET
T2 Biosystems Showcases Research from Recent Industry Conferences
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced poster session and abstract data showcasing results of its rapid diagnostic technologies at several industry conferences throughout...
Oct 04, 2021 04:05 pm ET
T2 Biosystems Announces BARDA Exercise of Contract Option 2A Valued at $6.4 Million
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness...
Sep 14, 2021 10:05 am ET
T2 Biosystems to Unveil New Data at September Conferences
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it will unveil new data at industry conferences this month to showcase results and implications of the use of its rapid diagnostics...
Sep 10, 2021 08:35 am ET
Thinking about buying stock in IVERIC bio, T2 Biosystems, Endo International, Arbutus Biopharma, or Katapult?
NEW YORK, Sept. 10, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ISEE, TTOO, ENDP, ABUS, and KPLT.
Sep 09, 2021 04:52 pm ET
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Mu B.1.621 and Iota B.1.526 Variants of the SARS-CoV-2 Virus
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is...
Sep 08, 2021 05:20 pm ET
T2 Biosystems Announces Plans to Consolidate and Expand Facilities in Massachusetts
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today plans to consolidate its existing facilities and expand into a newly leased facility in Billerica, Massachusetts. The Company will...
Sep 01, 2021 05:59 pm ET
T2 Biosystems Recognizes Sepsis Awareness Month with Thought Leadership Campaign and Participation in Sepsis Alliance Health Equity Pledge
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced efforts in recognition of Sepis Awareness Month to educate on the importance of rapid diagnostic technologies at a time when sepsis is...
Aug 05, 2021 04:05 pm ET
T2 Biosystems Announces Second Quarter 2021 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three months ended June 30, 2021. Recent Highlights Achieved second quarter 2021 revenue of $6.7 million,...
Aug 04, 2021 05:54 pm ET
T2 Biosystems to Participate in the Canaccord Genuity 41st Annual Growth Conference
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced plans to participate in the upcoming Canaccord Genuity 41st Annual Growth Conference. Management is scheduled to present Wednesday,...
Jul 22, 2021 04:05 pm ET
T2 Biosystems to Report Second Quarter 2021 Financial Results on August 5, 2021
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the second quarter of 2021 after market close on Thursday, August 5, 2021. Company management...
Jul 19, 2021 04:59 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to eleven new employees. The awards were made on July 8, 2021 under T2 Biosystems’ Inducement Award...
Jun 21, 2021 08:00 am ET
T2 Biosystems to Participate at Clinical Conferences in June and July 2021
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the Company’s participation in three virtual conferences this summer. The Company will take part in the American Society for...
Jun 11, 2021 09:00 am ET
World’s Leading Proxy Advisory Firms ISS and Glass Lewis Recommend T2 Biosystems Stockholders Vote “FOR” the Charter Amendment Proposal – To Increase the Number of Authorized Shares of Common Stock
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that leading proxy advisory firms Institutional Shareholder Services Inc. (ISS) and Glass Lewis and Co., LLC (Glass Lewis), in addition...
May 25, 2021 04:46 pm ET
T2 Biosystems Reminds Stockholders to Vote at the Upcoming Annual Meeting
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today reminded stockholders to vote at the upcoming 2021 Annual Meeting of Stockholders to be held on June 25, 2021. The T2 Biosystems Board of...
May 06, 2021 04:05 pm ET
T2 Biosystems Announces First Quarter 2021 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the three months ended March 31, 2021. Recent Highlights Achieved first quarter 2021 revenue of $7.0...
May 06, 2021 04:04 pm ET
T2 Biosystems Accelerates Product Development Initiatives Under Existing BARDA Contract
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that the Company has modified the terms of its existing contract with the Biomedical Advanced Research and Development Authority...
Apr 27, 2021 08:00 am ET
T2 Biosystems Announces Meta-analysis of Controlled Studies in Peer-Reviewed Medical Journal Highlighting the Benefits of T2MR Technology Compared to Blood Culture
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that Expert Review of Medical Devices, a peer-reviewed medical journal, published meta-analysis findings confirming that utilization of...
Apr 22, 2021 04:05 pm ET
T2 Biosystems to Report First Quarter 2021 Financial Results on May 6, 2021
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the first quarter of 2021 after market close on Thursday, May 6, 2021. Company management will...
Mar 30, 2021 08:00 am ET
T2 Biosystems CEO Shares Personal Heart Transplant and Sepsis Survival Story in Newly Released Book
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that CEO John Sperzel released a book about his personal experience with a bloodstream infection (BSI) and sepsis, titled “Courage:...
Mar 26, 2021 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to eighteen new employees. The awards were made on March 25, 2021 under T2 Biosystems’ Inducement...
Mar 04, 2021 04:05 pm ET
T2 Biosystems Announces Fourth Quarter & Full Year 2020 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended December 31, 2020. Recent Highlights Achieved 2020 revenue of $18.1...
Feb 24, 2021 08:31 am ET
Thinking about buying stock in Gamida Cell, Co-Diagnostics, T2 Biosystems, FSD Pharma, or Allena Pharmaceuticals?
NEW YORK, Feb. 24, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GMDA, CODX, TTOO, HUGE, and ALNA.
Feb 23, 2021 08:00 am ET
T2 Biosystems to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the fourth quarter and full year 2020 after market close on Thursday, March 4, 2021. Company...
Feb 08, 2021 04:07 pm ET
T2 Biosystems to Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming BTIG Virtual MedTech, Digital Health, Life Science & Diagnostics Tools Conference....
Feb 08, 2021 09:45 am ET
Thinking about buying stock in InspireMD, iBio, Nokia, Novan, or T2 Biosystems?
NEW YORK, Feb. 8, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NSPR, IBIO, NOK, NOVN, and TTOO.
Feb 05, 2021 07:35 am ET
Thinking about buying stock in T2 Biosystems, Sientra, Outlook Therapeutics, Biolase, or Boxlight Corp?
NEW YORK, Feb. 5, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, SIEN, OTLK, BIOL, and BOXL.
Feb 04, 2021 04:05 pm ET
T2 Biosystems T2SARS-CoV-2™ Panel Proves Capable of Detecting the Brazil P.1 Variant of the SARS-CoV-2 Virus
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is...
Feb 02, 2021 08:31 am ET
Thinking about buying stock in Durect Corp, T2 Biosystems, Gevo Inc, BioNano Genomics, or Advanced Micro Devices?
NEW YORK, Feb. 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for DRRX, TTOO, GEVO, BNGO, and AMD.
Jan 29, 2021 04:05 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, announced today that it issued an inducement award to Dr. Aparna Ahuja, the Company’s recently appointed Chief Medical Officer, in accordance...
Jan 26, 2021 04:44 pm ET
T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2020 Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced preliminary unaudited financial and operational results for the fourth quarter and full year 2020. Financial and Operational...
Jan 12, 2021 07:30 am ET
Thinking about buying stock in T2 Biosystems, Zomedica, Aldeyra Therapeutics, La Jolla Pharmaceutical, or US Well Services?
NEW YORK, Jan. 12, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, ZOM, ALDX, LJPC, and USWS.
Jan 11, 2021 06:19 pm ET
T2 Biosystems T2SARS-CoV-2™ Panel Proves Effective Amid Global Rise in Variants of the SARS-CoV-2 Virus
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel—a molecular diagnostic test that detects SARS-CoV-2, the virus responsible for COVID-19 infections—is...
Jan 07, 2021 08:00 am ET
T2 Biosystems Appoints Industry Expert Aparna Ahuja, MD as Chief Medical Officer
T2 Biosystems, Inc. (NASDAQ:TTOO), a global leader in the rapid detection of sepsis-causing pathogens, today announced that its Board of Directors has appointed Aparna Ahuja, MD, as Chief Medical Officer (CMO), effective immediately. In her new...
Dec 30, 2020 07:30 am ET
Thinking about buying stock in Hepion Pharmaceuticals, BioNano Genomics, T2 Biosystems, Surface Oncology, or Sesen Bio?
NEW YORK, Dec. 30, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for HEPA, BNGO, TTOO, SURF, and SESN.
Nov 12, 2020 04:31 pm ET
T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum. Management is scheduled to...
Nov 04, 2020 04:05 pm ET
T2 Biosystems Announces Third Quarter 2020 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the third quarter ended September 30, 2020. Recent Highlights Achieved record quarterly revenue of $5.2 million,...
Oct 19, 2020 04:42 pm ET
Sepsis Alliance Elects T2 Biosystems CEO as Advisory Board Member
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, and Sepsis Alliance, the first and leading sepsis nonprofit in the U.S., announced today that T2 Biosystems’ President and CEO, John Sperzel, will serve...
Oct 14, 2020 04:05 pm ET
T2 Biosystems to Report Third Quarter 2020 Financial Results on November 4, 2020
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the third quarter of 2020 after market close on Wednesday, November 4, 2020. Company...
Sep 30, 2020 09:00 am ET
T2 Biosystems Announces BARDA Exercise of Contract Option 1 Valued at $10.5 Million
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness...
Sep 16, 2020 08:00 am ET
T2 Biosystems to Participate in Sepsis Alliance Summit
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that it is participating in the virtual, inaugural Sepsis Alliance Summit taking place September 16-17, 2020, through a sponsorship and...
Sep 04, 2020 07:00 am ET
T2 Biosystems Announces CMS Approval of a New Technology Add-On Payment for the T2Bacteria® Panel for a Second Year
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) continued the New Technology Add-on Payment (NTAP) for the Company’s...
Aug 31, 2020 04:05 pm ET
T2 Biosystems Receives FDA Emergency Use Authorization for COVID-19 Molecular Diagnostic Test
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for its COVID-19 molecular diagnostic...
Aug 11, 2020 04:05 pm ET
T2 Biosystems Announces Second Quarter 2020 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the second quarter ended June 30, 2020. Recent Highlights Achieved second quarter total revenue of $2.6 million...
Aug 05, 2020 07:30 am ET
T2 Biosystems Announces Withdrawal of Proxy Statement Proposal to Amend Its Certificate of Incorporation to Authorize a Possible Reverse Stock Split
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that its Board of Directors has decided it will not seek authority from the stockholders at the 2020 Annual Meeting (“Annual Meeting”)...
Aug 04, 2020 09:31 am ET
Thinking about trading options or stock in Varian Medical Systems, Sorrento Therapeutics, T2 Biosystems, Ford Motor, or American Airlines?
NEW YORK, Aug. 4, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VAR, SRNE, TTOO, F, and AAL.
Jul 30, 2020 04:05 pm ET
T2 Biosystems to Participate in the Canaccord Genuity Annual Growth Conference
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming virtual Canaccord Genuity Annual Growth Conference. Management is scheduled to...
Jul 28, 2020 04:05 pm ET
T2 Biosystems to Report Second Quarter 2020 Financial Results on August 11, 2020
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the second quarter of 2020 after market close on Tuesday, August 11, 2020. Company management...
Jul 16, 2020 09:31 am ET
Thinking about buying stock in Ashford Hospitality Trust, Boxlight Corp, T2 Biosystems, Southwest Airlines, or Heat Biologics?
NEW YORK, July 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AHT, BOXL, TTOO, LUV, and HTBX.
Jul 01, 2020 09:31 am ET
Thinking about buying stock in T2 Biosystems, Ameresco Inc, Xeris Pharmaceuticals, Blink Charging, or Kitov Pharma?
NEW YORK, July 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TTOO, AMRC, XERS, BLNK, and KTOV.
Jun 30, 2020 04:06 pm ET
T2 Biosystems Announces U.S. Launch of COVID-19 Diagnostic Test
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the completion of validation of its COVID-19 molecular diagnostic test, the T2SARS-CoV-2 Panel. The test was developed by T2 Biosystems...
Jun 30, 2020 04:04 pm ET
T2 Biosystems Announces Preliminary Second Quarter 2020 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited preliminary financial result estimates for the quarter ended June 30, 2020. In addition, the Company announced the U.S. launch...
Jun 26, 2020 08:00 am ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees. The awards were made on May 5, 2020 and June 2, 2020 under T2 Biosystems’...
Jun 17, 2020 07:30 am ET
T2 Biosystems Regains Compliance with NASDAQ Listing Requirements
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that on June 16, 2020 it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC (“Nasdaq”)...
Jun 15, 2020 04:06 pm ET
T2 Biosystems Announces Changes to Board of Directors
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced three new Board of Director appointments. The three new directors will add significant clinical and commercialization experience and...
Jun 12, 2020 09:31 am ET
Thinking about buying stock in Valaris PLC, T2 Biosystems, Seanergy Maritime, Global Eagle Entertainment, or Penn National Gaming?
NEW YORK, June 12, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VAL, TTOO, SHIP, ENT, and PENN.
Jun 10, 2020 09:31 am ET
Thinking about buying stock in Lakeland Industries, Capricor Therapeutics, T2 Biosystems, Callon Petroleum, or TOP Ships?
NEW YORK, June 10, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LAKE, CAPR, TTOO, CPE, and TOPS.
Jun 03, 2020 09:31 am ET
Thinking about buying stock in Digital Turbine, Mattel, T2 Biosystems, Altimmune, or Moneygram International?
NEW YORK, June 3, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for APPS, MAT, TTOO, ALT, and MGI.
May 19, 2020 10:30 am ET
Thinking about buying stock in Oragenics Inc, T2 Biosystems, Norwegian Cruise Lines, Sea Limited, or cbdMD Inc?
NEW YORK, May 19, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OGEN, TTOO, NCLH, SE, and YCBD.
May 19, 2020 08:30 am ET
T2 Biosystems’ Bacteria Panel Wins “Best New Technology Solution - Diagnostics" Award in MedTech Breakthrough Awards
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it won the “Best New Technology Solution - Diagnostics" award for its T2Bacteria® Panel solution in the fourth annual MedTech...
May 05, 2020 04:05 pm ET
T2 Biosystems Announces First Quarter 2020 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the first quarter ended March 31, 2020. Recent Highlights Achieved first quarter total revenue of $2.5 million...
Apr 21, 2020 04:22 pm ET
T2 Biosystems to Report First Quarter 2020 Financial Results on May 5, 2020
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it will report financial results for the first quarter of 2020 after market close on Tuesday, May 5, 2020. Company management will...
Apr 15, 2020 05:06 pm ET
T2 Biosystems Reports Granting of Inducement Award
T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees. The awards were made on March 18, 2020 and April 14, 2020 under T2 Biosystems’...
Mar 27, 2020 09:31 am ET
Thinking about buying stock in Aytu Bioscience, GameStop, Translate Bio, Tilray, or T2 Biosystems?
NEW YORK, March 27, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AYTU, GME, TBIO, TLRY, and TTOO.
Mar 24, 2020 04:31 pm ET
T2 Biosystems Announces Worldwide Licensing Agreement of COVID-19, Novel Coronavirus Assay from Hackensack Meridian Health’s Center for Discovery and Innovation
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that it has entered into a worldwide licensing agreement for a rapid COVID-19, novel coronavirus test developed by the Center of...
Mar 24, 2020 04:30 pm ET
T2 Biosystems Announces Preliminary First Quarter 2020 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced unaudited, preliminary financial result estimates for the quarter ended March 31, 2020, and suspended full year 2020 financial and...
Mar 19, 2020 08:00 am ET
T2 Biosystems Receives Multiyear Innovative Technology Contract from Vizient, Inc.
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that it was awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement...
Feb 24, 2020 04:05 pm ET
T2 Biosystems Announces Fourth Quarter and Full Year 2019 Financial Results
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced financial results for the fourth quarter and full year ended December 31, 2019. Fourth Quarter and Recent Business and Financial...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.